Clinical Trial

A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors

Name: A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors — clinical trial record (NCT07269899)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Reboot-107

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a single-arm, open-label, investigator-initiated clinical study (IIT) designed to evaluate the preliminary efficacy, safety, tolerability, immunogenicity, and pharmacokinetic (PK) characteristics of WTX212A Injection in patients with advanced solid tumors.

Trial Details

NCT Number	NCT07269899
Lead Sponsor	Sun Yat-sen University Collaborators: Westlake Therapeutics
Conditions	Solid Tumor Cancer, Cancer
Enrollment	12 participants
Start Date	2025-11-25
Primary Completion	2027-02-28 (estimated)
Study Completion	2027-08-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-08